The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
While Cogent joins the FGFR party.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Just when investors thought things couldn't get any worse, they do.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.